Increasing Prevalence of Chronic Diseases to Augment the Hospital Pharmaceuticals Market Growth

Hospital pharmaceuticals consist of medicines purchased for hospitals, healthcare centers to be administered to patients during hospitalization. Hospital pharmaceuticals include therapeutic and critical care drugs applied in infections, neurology, urology, cardiology, hematology, dermatology, respiratory system, musculoskeletal system, sensory organs, alimentary tract and metabolism, and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications.

Market Dynamics:

Increasing incidence or prevalence of chronic diseases across the world, especially in the North America, is expected to propel the growth of the hospital pharmaceuticals market. For instance, chronic diseases such as diabetes, cancer, and heart disease, are the leading causes of death and disability in the United States, according to the Centers for Disease Control and Prevention (CDC). They are also leading drivers of the nation's $3.8 trillion in annual health care costs.

Moreover, the emergence of COVID-19 (SARS-CoV-2) is expected to augment the growth of the hospital pharmaceuticals market. For instance, in February 2021, Facing the challenge of a fast-paced and complex rollout of COVID-19 vaccines, Pennsylvania Hospital deployed radio frequency identification (RFID) technology to track the status of every vial that is removed from an ultra-freezer, then transported to the vaccination clinic, and sometimes returned to refrigeration, all while ensuring no vial expires before reaching a patient's arm.

Increasing demand for hospital pharmaceuticals and increasing spending on pharmaceuticals is also expected to fuel the growth of the hospital pharmaceuticals market. However,

Competitive Analysis:

Major players operating in the hospital pharmaceuticals market are Eli Lilly and Company, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline Plc., AstraZeneca Plc., Pfizer, Inc., Novartis AG, and Bayer AG.

Major players in the market are adopting various strategies, such as partnership, collaboration, product launch, etc., to enhance their market presence. For instance, in February 2021, Recce Pharma Ltd. formalized an agreement with Fiona Stanley Hospital for a Phase 1/2 clinical trial to assess the potential of RECCE 327’s new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections.

In February 2021, Algernon Pharmaceuticals provided an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.

In February 2021, Valeo Pharma and Ingenew Pharma announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's clinical trial, "The Hesperidin Coronavirus Study".

Comments

Life Sciences BPO Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

The growing cost of drug development is augmenting the growth of the global life sciences BPO market. For instance, according to a study by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019, the cost of drug development was US$ 2.6 billion, which included average out-of-pocket costs of US$ 1.4 billion and time costs of US$ 1.2 billion. Also, patent expiration is another key factor propelling the growth of the life sciences BPO market. For instance, the patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021. Furthermore, the rising prevalence of chronic disease around the globe is further anticipated to accelerate the growth of the market. North America is projected to lead the global life sciences BPO market due to increasing R&D in cell therapies by key players in the region. For instance, in February 2020, Caribou Biosciences, Inc., a CRISPR genome editin

Increasing various research activities is propelling growth of the pediatric vaccines market

Pediatric Vaccine Market: Global Trends Over the course of the forecast period, rising public awareness of vaccinations and immunisation is anticipated to fuel market expansion for paediatric vaccines worldwide. For instance, the United States recognises January as Cervical Health Awareness Month, promoting the value of routine immunisation and screening in the fight against cancer. Global Pediatric Vaccine Market: Drivers Increasing awareness regarding vaccines and immunization among the populace is expected to boost growth of the global pediatric vaccine market over the forecast period. For instance, in the U.S., the month of January is celebrated as Cervical Health Awareness Month, wherein the importance of regular vaccination and screening in the prevention of cancer is forwarded.

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: · Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe · Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe · Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering takes place and which layer of skin is affected. Global epidermolysis bullosa market is estimated to be valued at US$ 3,

Healthcare News

Search This Blog